Genotype
|
Patients (n = 213)
|
Controls (n = 958)
|
P
a
|
Crude OR (95% CI)
|
P
|
Adjusted OR (95% CI)b
|
P
b
|
---|
NRAS rs2273267 A > T (HWE = 0.794)
|
AA
|
103 (48.36)
|
486 (50.73)
| |
1.00
| |
1.00
| |
AT
|
88 (41.31)
|
395 (41.23)
| |
1.05 (0.77–1.44)
|
0.755
|
1.05 (0.77–1.44)
|
0.758
|
TT
|
22 (10.33)
|
77 (8.04)
| |
1.35 (0.80–2.27)
|
0.259
|
1.35 (0.80–2.27)
|
0.259
|
Additive
| | |
0.528
|
1.12 (0.89–1.40)
|
0.338
|
1.12 (0.89–1.40)
|
0.338
|
Dominant
|
110 (51.64)
|
472 (49.27)
|
0.531
|
1.10 (0.82–1.48)
|
0.531
|
1.10 (0.82–1.48)
|
0.532
|
Recessive
|
191 (89.67)
|
881 (91.96)
|
0.277
|
1.32 (0.80–2.17)
|
0.278
|
1.32 (0.80–2.17)
|
0.277
|
KRAS rs12587 G > T (HWE = 0.132)
|
GG
|
128 (60.09)
|
609 (63.57)
| |
1.00
| |
1.00
| |
GT
|
79 (37.09)
|
300 (31.32)
| |
1.25 (0.92–1.71)
|
0.158
|
1.26 (0.92–1.72)
|
0.155
|
TT
|
6 (2.82)
|
49 (5.11)
| |
0.58 (0.24–1.39)
|
0.223
|
0.58 (0.24–1.39)
|
0.223
|
Additive
| | |
0.130
|
1.04 (0.80–1.34)
|
0.789
|
1.04 (0.80–1.34)
|
0.788
|
Dominant
|
85 (39.91)
|
349 (36.43)
|
0.342
|
1.16 (0.86–1.57)
|
0.342
|
1.16 (0.86–1.57)
|
0.341
|
Recessive
|
207 (97.18)
|
909 (94.89)
|
0.152
|
0.54 (0.23–1.27)
|
0.158
|
0.54 (0.23–1.27)
|
0.158
|
KRAS rs7973450 A > G (HWE = 0.213)
|
AA
|
178 (83.57)
|
798 (83.30)
| |
1.00
| |
1.00
| |
AG
|
35 (16.43)
|
156 (16.28)
| |
1.01 (0.67–1.50)
|
0.977
|
1.01 (0.67–1.50)
|
0.979
|
GG
|
0 (0.00)
|
4 (0.42)
| |
/
|
/
|
/
|
/
|
Additive
| | |
0.640
|
0.95 (0.65–1.41)
|
0.814
|
0.95 (0.65–1.41)
|
0.811
|
Dominant
|
35 (16.43)
|
160 (16.70)
|
0.924
|
0.98 (0.66–1.46)
|
0.924
|
0.98 (0.66–1.46)
|
0.921
|
Recessive
|
213 (100.00)
|
954 (99.58)
|
0.345
|
/
|
/
|
/
|
/
|
KRAS rs7312175 G > A (HWE = 0.300)
|
GG
|
167 (78.40)
|
740 (77.24)
| |
1.00
| |
1.00
| |
GA
|
44 (20.66)
|
200 (20.88)
| |
0.98 (0.68–1.41)
|
0.892
|
0.98 (0.68–1.41)
|
0.892
|
AA
|
2 (0.94)
|
18 (1.88)
| |
0.49 (0.11–2.14)
|
0.345
|
0.49 (0.11–2.15)
|
0.345
|
Additive
| | |
0.626
|
0.91 (0.65–1.26)
|
0.553
|
0.91 (0.65–1.26)
|
0.554
|
Dominant
|
46 (21.60)
|
218 (22.76)
|
0.714
|
0.94 (0.65–1.34)
|
0.714
|
0.94 (0.65–1.34)
|
0.715
|
Recessive
|
211 (99.06)
|
940 (98.12)
|
0.338
|
0.50 (0.11–2.15)
|
0.348
|
0.50 (0.11–2.15)
|
0.348
|
Combined effect of protective genotypesc
|
0
|
139 (65.26)
|
605 (63.15)
| |
1.00
| |
1.00
| |
1
|
63 (29.58)
|
303 (31.63)
| |
0.91 (0.65–1.26)
|
0.551
|
0.91 (0.65–1.26)
|
0.552
|
2
|
9 (4.23)
|
26 (2.71)
| |
1.51 (0.69–3.29)
|
0.303
|
1.51 (0.69–3.29)
|
0.302
|
3
|
2 (0.94)
|
24 (2.51)
| |
0.36 (0.09–1.55)
|
0.172
|
0.36 (0.09–1.55)
|
0.172
|
Trend
| | |
0.306
|
0.92 (0.73–1.16)
|
0.458
|
0.92 (0.73–1.16)
|
0.458
|
0
|
139 (65.26)
|
605 (63.15)
| |
1.00
| |
1.00
| |
1–3
|
74 (34.74)
|
353 (36.85)
|
0.564
|
0.91 (0.67–1.25)
|
0.564
|
0.91 (0.67–1.25)
|
0.561
|
- OR odds ratio, CI confidence interval, HWE Hardy–Weinberg equilibrium
- aBy χ2 test vs. cancer-free controls
- bAdjusted for age and gender
- cRisk genotypes are rs12587 TT, rs7973450 AG/GG, and rs7312175 GA/AA